Ongoing sensory or motor neuropathy Grade ?2.Xx_NEWLINE_xXNervous system disorder (paresthesia, peripheral motor neuropathy, or peripheral sensory neuropathy) >= grade 2, per the Common Terminology Criteria for Adverse Events (CTCAE) version (v)4.0Xx_NEWLINE_xXNo grade >= 2 peripheral motor or sensory neuropathyXx_NEWLINE_xXNeuropathy (sensory and motor) =< CTCAE v 3.0 grade 1Xx_NEWLINE_xX>= Grade 2 peripheral sensory neuropathy (CTCAE, v. 4.0)Xx_NEWLINE_xXNeuropathy (sensory and motor) less than or equal to CTCAE grade 1Xx_NEWLINE_xXPatients must have < grade 2 neuropathy (sensory/motor) within 7 days prior to registrationXx_NEWLINE_xXAdverse events from prior anti-cancer therapy resolved to Grade < or = 1, except any grade alopecia and/or peripheral sensory or motor neuropathy which must have resolved to Grade < or = 2Xx_NEWLINE_xXPersisting toxicity related to prior therapy (NCI CTCAE v. 4.03 Grade > 1); however, alopecia, sensory neuropathy Grade ? 2, or other Grade ? 2 not constituting a safety risk based on Investigator's judgment are acceptable.Xx_NEWLINE_xXFailure to recover from acute, reversible effects of prior therapy regardless of interval since last treatment\r\n* EXCEPTION: Grade 1 peripheral (sensory) neuropathy that has been stable for at least 3 months since completion of prior treatmentXx_NEWLINE_xXSubject has preexisting sensory or motor neuropathy Grade ? 2 at baselineXx_NEWLINE_xXParticipants with grade >= 3 peripheral motor or sensory neuropathyXx_NEWLINE_xXNeuropathy (sensory and motor) NCI CTCAE grade =< 2Xx_NEWLINE_xXNeuropathy (sensory and motor) less than or equal to CTCAE v4.0, grade 1Xx_NEWLINE_xXPatients who have pre-existing motor or sensory neuropathy of a severity ? grade 1 by CTCAE v4.0 criteriaXx_NEWLINE_xXResolution of all chemotherapy-related or radiation-related toxicities to grade 1 severity or lower, except for stable sensory neuropathy (=< grade 2 allowed) and alopecia (of any grade)Xx_NEWLINE_xXNervous system disorder (paresthesias, peripheral motor neuropathy, or peripheral sensory neuropathy) ? Grade 2, per the CTCAE v4.0.Xx_NEWLINE_xXGrade ? 3 sensory or motor neuropathy.Xx_NEWLINE_xXHas not recovered from adverse reactions to prior myeloma treatment or procedures (chemotherapy, immunotherapy, radiation therapy) to NCI CTCAE less than or equal to (<=) Grade 1 or baseline, except for sensory or motor neuropathy which should have recovered to <=Grade 2 or baseline.Xx_NEWLINE_xXResolution of all chemotherapy-related or radiation-related toxicities to grade 1 severity or lower, except for stable sensory neuropathy (=< grade 2) and alopeciaXx_NEWLINE_xXPatients with > grade 2 sensory peripheral neuropathy.Xx_NEWLINE_xXFailure to recover from acute, reversible effects of prior therapy regardless of interval since last treatment\r\n* NOTE: Patients can have peripheral (sensory) neuropathyXx_NEWLINE_xXPersisting toxicity (except alopecia and vitiligo) related to prior oncologic therapy grade > 1 NCI-CTCAE v4.03, however, sensory neuropathy grade =< 2 is acceptable.Xx_NEWLINE_xXSensory or motor neuropathy ? grade 2Xx_NEWLINE_xXPatients must have recovered from adverse events due to prior treatment to ? grade 1, except for alopecia and sensory neuropathy ? grade 2Xx_NEWLINE_xXPersisting toxicity related to prior therapy of grade > 1 NCI-CTCAE v 4.03; however, alopecia and sensory neuropathy grade =< 2 is acceptable.Xx_NEWLINE_xXPreexisting sensory neuropathy Grade ? 2Xx_NEWLINE_xXPreexisting motor neuropathy Grade ? 2Xx_NEWLINE_xXPatients must have recovered from adverse events attributable to previous treatment to =< grade 1, except for alopecia and sensory neuropathy =< grade 2Xx_NEWLINE_xXPersisting toxicity related to prior therapy (NCI CTCAE v. 4.03 grade > 2); however, alopecia, sensory neuropathy grade ? 2, or other grade ? 2 not constituting a safety risk based on investigator’s judgment are acceptableXx_NEWLINE_xXNeuropathy (sensory and motor) less than or equal to CTCAE v4.03 grade 1Xx_NEWLINE_xXPeripheral neuropathy >= grade 3 sensory neuropathy or >= grade 2 sensory neuropathy with pain within 14 days of registration; prior neuropathy of this severity improved due to medical management such as gabapentin are potentially eligibleXx_NEWLINE_xXSensory/peripheral neuropathy.Xx_NEWLINE_xXPersisting toxicity related to prior therapy (NCI CTCAE v. 4.03 Grade > 1); however, alopecia, sensory neuropathy grade =< 2, or other grade =< 2 not constituting a safety risk based on investigator’s judgment are acceptable.Xx_NEWLINE_xXPersisting toxicity related to prior therapy (NCI CTCAE v. 4.03 grade > 1); however, alopecia, sensory neuropathy grade ? 2, or other grade ? 2 not constituting a safety risk based on investigator’s judgment are acceptableXx_NEWLINE_xXPre-existing > grade 2 peripheral sensory neuropathyXx_NEWLINE_xXPersisting toxicity related to prior therapy of grade > 1 NCI-CTCAE v 4.03; however, alopecia and sensory neuropathy grade =< 2 is acceptableXx_NEWLINE_xXPre-existing sensory neuropathy of grade >= 2Xx_NEWLINE_xXSensory or motor neuropathy >= grade 2Xx_NEWLINE_xXPersisting toxicity related to prior therapy (NCI CTCAE v. 4.03 grade > 1); however, alopecia, sensory neuropathy grade =< 2, or other grade =< 2 not constituting a safety risk based on investigator’s judgment are acceptableXx_NEWLINE_xXPersisting toxicity related to prior therapy of grade > 1 NCI-CTCAE v 4.03; however, alopecia and sensory neuropathy grade =< 2 is acceptableXx_NEWLINE_xXPersisting toxicity related to prior therapy of grade > 1 NCI-CTCAE v 4.03; however, alopecia and sensory neuropathy grade =< 2 is acceptableXx_NEWLINE_xXGrade 2 sensory or Grade 1 painful peripheral neuropathyXx_NEWLINE_xXOngoing sensory or motor neuropathy Grade 2 or higher.Xx_NEWLINE_xXSensory or motor neuropathy >= Grade 2.Xx_NEWLINE_xXRecovered from any previous therapy related toxicity to =< grade 1 or baseline at study entry (except for stable sensory neuropathy =< grade 2 and alopecia)Xx_NEWLINE_xXNervous system disorder (i.e., paresthesia, peripheral motor neuropathy, or peripheral sensory neuropathy) >= grade 2, per Common Terminology Criteria for Adverse Events (CTCAE) version (v)4.0Xx_NEWLINE_xXPersisting toxicity related to prior therapy of grade > 1 NCI-CTCAE v 4.03; however, alopecia and sensory neuropathy grade =< 2 is acceptableXx_NEWLINE_xXPatient has >= grade 2 neuropathy, sensory, with or without pain, motor, or autonomic, on clinical examination during the screening periodXx_NEWLINE_xXPatients must not have > grade sensory neuropathyXx_NEWLINE_xXNo baseline peripheral sensory neuropathy >= grade 2Xx_NEWLINE_xXPatients with evidence of >= grade 2 peripheral sensory neuropathyXx_NEWLINE_xXNervous system disorder (paresthesias, peripheral motor neuropathy, or peripheral sensory neuropathy) >= grade 2, per the Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0)Xx_NEWLINE_xXPre-existing grade >= 2 peripheral sensory neuropathyXx_NEWLINE_xXNo >= grade 2 sensory peripheral neuropathyXx_NEWLINE_xXPeripheral sensory neuropathy at the thumbs bilaterally that interferes with function and/or activities of daily livingXx_NEWLINE_xXPatients must not have grade 2 or greater peripheral sensory neuropathyXx_NEWLINE_xXRANDOMIZED PHASE II (ARMS K AND L): Patients must not have grade 2 or greater peripheral sensory neuropathyXx_NEWLINE_xXSensory peripheral neuropathy >= grade 2Xx_NEWLINE_xXPatients with pre-existing grade 2 or greater peripheral neuropathy, defined as sensory alteration or paresthesia (including tingling), interfering with functionXx_NEWLINE_xXNeuropathy (sensory and motor) =< to CTCAE grade 1Xx_NEWLINE_xXPatients with symptomatic peripheral motor or sensory neuropathy >= grade 2 at baseline will receive radiation therapy aloneXx_NEWLINE_xXSubject has known peripheral sensory neuropathy > Grade 1 unless the absence of deep tendon reflexes is the sole neurological abnormality.Xx_NEWLINE_xXPersistent grade > 1 clinically significant toxicities related to prior antineoplastic therapies (except for alopecia); stable sensory neuropathy ? grade 1 NCI-CTCAE v. 4.0 is allowed.Xx_NEWLINE_xXBaseline peripheral sensory neuropathy ? grade 2Xx_NEWLINE_xXNeuropathy (sensory and motor) less than or equal to grade 1 per Common Toxicity Criteria (CTC) version 4Xx_NEWLINE_xXGrade 3 sensory neuropathy or motor neuropathy with painXx_NEWLINE_xXNervous system disorder (paresthesia, peripheral motor neuropathy, or peripheral sensory neuropathy) >= grade 2, per the Common Terminology Criteria for Adverse Events (CTCAE) version (v) 5.0Xx_NEWLINE_xXSensory/motor neuropathy >= grade 2Xx_NEWLINE_xXSensory/motor neuropathy >= grade 2Xx_NEWLINE_xXPatients with any of the following adverse events at the time of enrollment are not eligible:\r\n* Grade ? 2 motor, sensory or peripheral neuropathy\r\n* Grade ? 3 hyponatremia (serum sodium [Na] ? 130 mmol/L)Xx_NEWLINE_xXParticipant must have either no neuropathy (sensory and motor) or neuropathy less than or equal to grade 1Xx_NEWLINE_xXPatients with persistent grade 2 or higher peripheral sensory or motor neuropathy of any causeXx_NEWLINE_xXSensory or motor peripheral neuropathy >= grade 2Xx_NEWLINE_xXSensory or motor neuropathy >= grade 2Xx_NEWLINE_xXSubject has preexisting sensory or motor neuropathy Grade ? 2 at baselineXx_NEWLINE_xXPre-existing >= grade 2 sensory or motor peripheral neurotoxicityXx_NEWLINE_xXPatients must have recovered to =< grade 1 adverse events or to =< grade 2 alopecia and sensory neuropathy due to prior treatmentXx_NEWLINE_xXBaseline of grade 2 or worse peripheral sensory neuropathyXx_NEWLINE_xXPatients must not have a pre-existing > grade 1 motor or sensory neuropathyXx_NEWLINE_xXPHASE II: Patients must not have a pre-existing > grade 1 motor or sensory neuropathyXx_NEWLINE_xXNervous system disorder (paresthesia, peripheral motor neuropathy, or peripheral sensory neuropathy) >= grade 2, per the Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0)Xx_NEWLINE_xXNeuropathy (sensory and motor) =< grade 1Xx_NEWLINE_xXNeuropathy (sensory and motor) less than or equal to CTEP CTCAE version 4.0, grade 1Xx_NEWLINE_xXPre-existing peripheral motor or sensory neuropathy >= grade 2Xx_NEWLINE_xXNeuropathy (sensory and motor) less than or equal to Grade 1.Xx_NEWLINE_xXParticipant with sensory peripheral neuropathy of ? Grade 2 at baseline, unable to swallow medication, or participants with prior history of seizure within the prior 12 months.Xx_NEWLINE_xXPatients must have recovered from adverse events attributable to previous treatment to =< grade 1, except for alopecia and sensory neuropathy =< grade 2Xx_NEWLINE_xXPreexisting sensory grade 3 neuropathyXx_NEWLINE_xXPreexisting sensory neuropathy Grade ? 2 or motor neuropathy Grade ? 2Xx_NEWLINE_xXPersisting toxicity related to prior therapy Grade > 1 NCI-CTCAE v 4.0; however, sensory neuropathy Grade <= 2 is acceptable 14. Pregnancy or lactationXx_NEWLINE_xXAdverse events except for sensory neuropathy from any previous treatments must be resolved or stabilized to Grade less than equal to (</=) 2 prior study startXx_NEWLINE_xXMotor neuropathy considered of autoimmune originXx_NEWLINE_xXSensory or motor peripheral neuropathyXx_NEWLINE_xXPreexisting sensory grade >= 2 neuropathyXx_NEWLINE_xXResolution of grade 2 and above toxicities of most recent therapy except for stable sensory neuropathy (=< grade 2) and alopeciaXx_NEWLINE_xXPatients who have not recovered from adverse events to grade 1 severity or lower due to agents administered more than 2 weeks earlier than registration, are not eligible, except for stable sensory neuropathy (=< grade 2) and alopeciaXx_NEWLINE_xXCurrent peripheral sensory neuropathy > grade 1Xx_NEWLINE_xXRecovery to ? Grade 1 or baseline of any toxicities, except for stable sensory neuropathy ? Grade 2 and alopeciaXx_NEWLINE_xXNeuropathy (sensory and motor) less than or equal to grade 1Xx_NEWLINE_xXNeuropathy (sensory and motor) less than or equal to grade 1Xx_NEWLINE_xXPreexisting sensory and/or motor neuropathy Grade ? 2Xx_NEWLINE_xXExistence of peripheral sensory neuropathy >= grade 2 (from any cause)Xx_NEWLINE_xXPatients with grade 2 sensory neuropathy at baselineXx_NEWLINE_xXPre-existing grade 3 or 4 sensory neuropathyXx_NEWLINE_xXHistory of severe motor or sensory neuropathy, or any other autoimmune disorder which is deemed to be significantXx_NEWLINE_xXPatient has >= grade 3 peripheral sensory neuropathy or >= grade 2 painful sensory neuropathy within 14 days before enrollment; (NOTE: patient with peripheral neuropathy [PN] that was previously this severe but is currently improved due to ongoing therapy [e.g., gabapentin or amitriptyline] may be eligible)Xx_NEWLINE_xXCTC Grade 1 or greater neuropathy (motor or sensory) from comorbidity other than prior taxane exposure, such as diabetes.Xx_NEWLINE_xXGrade >= 2 sensory neuropathy at the time of enrollmentXx_NEWLINE_xXNo peripheral or sensory neuropathy > grade 1 at study entryXx_NEWLINE_xXPreexisting sensory grade >= 2 neuropathyXx_NEWLINE_xXNeuropathy (sensory and motor) less than or equal to CTCAE grade 1Xx_NEWLINE_xXNeuropathy(Both motor and sensory) ? Grade1 (CTCAE Version 4.0)Xx_NEWLINE_xXNeuropathy (sensory and motor) =< grade 1 according to Common Toxicity Criteria for Adverse Events version 3 (CTCAE)Xx_NEWLINE_xXNeuropathy (sensory and motor) less than or equal to grade 1Xx_NEWLINE_xXPersisting toxicity related to prior therapy of NCI CTCAE grade >1 severity. Sensory neuropathy of grade ?2 is acceptable.Xx_NEWLINE_xX?Grade 2 sensory neuropathy at baselineXx_NEWLINE_xXNeuropathy (sensory and motor) less than or equal to CTCAE v 4.0 grade 1Xx_NEWLINE_xXPatients with pre-existing Grade 2 (or greater) peripheral motor or sensory neurotoxicity per the CTCAE 3.0 as determined by the treating physician or a neurologist.Xx_NEWLINE_xXEvidence of baseline sensory or motor neuropathyXx_NEWLINE_xXSensory peripheral neuropathy greater than or equal to (>/=) Grade 2Xx_NEWLINE_xXEvidence of sensory and/or peripheral neuropathy > grade 1Xx_NEWLINE_xXNeuropathy (sensory and motor) =< CTCAE v4.03 grade 1Xx_NEWLINE_xXPatients must have recovered from adverse events attributable to previous treatment to =< grade 1, except for alopecia and sensory neuropathy =< grade 2Xx_NEWLINE_xXResolution of all chemotherapy-related or radiation-related toxicities to Grade 1 severity or lower, except for stable sensory neuropathy (<= Grade 2) and alopecia.Xx_NEWLINE_xXGrade ? 2 sensory neuropathyXx_NEWLINE_xXSignificant peripheral sensory or motor neuropathy at the start of the study.Xx_NEWLINE_xXHas sensory or motor neuropathy limiting daily activities.Xx_NEWLINE_xXNeurologic function: neuropathy (sensory and motor) ? CTCAE Grade 1Xx_NEWLINE_xXCurrent/ongoing Neuropathy (sensory or motor) Grade > 1 or any history of Grade ? 3 neuropathy with prior Vincristine or chemotherapy exposure (documentation by history is adequate to exclude)Xx_NEWLINE_xXGreater than grade 2 motor neuropathy or greater than grade 3 sensory neuropathy at screeningXx_NEWLINE_xXSubjects with sensory neuropathy, ascites, or plastic biliary stent.Xx_NEWLINE_xXRecovered from any previous therapy related toxicity to <= Grade 1 at study entry (except for stable sensory neuropathy <= Grade 2 and alopecia)Xx_NEWLINE_xXSensory peripheral neuropathy greater than or equal to (>/=) Grade 2Xx_NEWLINE_xXGrade ? 2 sensory neuropathyXx_NEWLINE_xXEvidence of grade 2 or greater sensory and/or peripheral neuropathyXx_NEWLINE_xXNeuropathy (sensory and motor) less than or equal to CTCAE grade 1Xx_NEWLINE_xXNo evidence of peripheral or sensory neuropathyXx_NEWLINE_xXGrade 2 or greater motor or sensory neuropathyXx_NEWLINE_xXPatient does not have a clinically significant neurologic deficit or objective peripheral neuropathy (greater than or equal to grade 2); peripheral (sensory or motor) neuropathy related to limb sparing procedure or amputation is allowedXx_NEWLINE_xXPatients with >= grade 2 sensory or motor neuropathy are not eligibleXx_NEWLINE_xXNeuropathy (sensory or motor) less than or equal to grade 1Xx_NEWLINE_xXChemotherapy-related or radiation-related toxicities that have not resolved to grade 1 severity or lower, except for stable sensory neuropathy (=< grade 2) and alopeciaXx_NEWLINE_xXMajor sensory or motor impairment that would preclude valid cognitive testingXx_NEWLINE_xXAble to perform motor/sensory testsXx_NEWLINE_xXPatients with > grade 2 sensory peripheral neuropathyXx_NEWLINE_xXPatients with ? grade 2 sensory peripheral neuropathyXx_NEWLINE_xXSensory/motor neuropathy ? Grade 2Xx_NEWLINE_xXPersisting toxicity related to prior therapy (NCI CTCAE v. 4.03 grade > 1); however, alopecia, sensory neuropathy grade =< 2, or other grade =< 2 not constituting a safety risk based on investigator’s judgment are acceptableXx_NEWLINE_xXPersisting toxicity related to prior therapy of grade > 1 NCI-CTCAE v 4.03; however, alopecia and sensory neuropathy grade =< 2, or other grade =< 2 not constituting a safety risk based on investigator’s judgment, are acceptableXx_NEWLINE_xXPre-existing sensory neuropathy > grade 1Xx_NEWLINE_xXCurrent or prior history of grade ? 2 peripheral sensory and/or motor neuropathy.Xx_NEWLINE_xX